Study Title
Restoration of Radioiodine Uptake With Selpercatinib in RET Fusion-Positive Radioiodine-Refractory Thyroid Cancer: A Phase 2 Study Performed in Collaboration With the International Thyroid Oncology Group (ITOG)
Study Details
Description:
This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research study involves the study drug selpercatinib in combination with standard of care treatments, I-131 and thyrotropin alfa (rhTSH).
Sponsor:
Massachusetts General Hospital
Contacts:
Lori J. Wirth, MD (Principal Investigator)lwirth@mgh.harvard.edu
617-724-1134
Government Study Link:
NCT05668962 - Click here to see study onClinicalTrials.gov